5-azidohexanoic acid | 1361944-05-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-azidohexanoic acid
• 英文别名: 5-Azidohexanoic acid
• CAS: 1361944-05-9
• 化学式: C₆H₁₁N₃O₂
• 分子量: 157.172
• InChiKey: ZUDFNRDVFKNJOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  51.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-己烯酸 在 sodium tetrahydroborate 、 sodium azide 、 ferric tartrate 作用下， 以 乙醇 、 水 为溶剂， 反应 0.58h， 以69%的产率得到5-azidohexanoic acid
  参考文献：
  名称：

  Iron(III)/NaBH₄-Mediated Additions to Unactivated Alkenes: Synthesis of Novel 20′-Vinblastine Analogues

  摘要：

  An Fe(III)/NaBH4-mediated reaction for the functionalization of unactivated alkenes is described defining the alkene substrate scope, establishing the exclusive Markovnikov addition, exploring a range of free radical traps, examining the Fe(III) salt and initiating hydride source, introducing H2O-cosolvent mixtures, and exploring catalytic variants. Its use led to the preparation of a novel, potent, and previously inaccessible C20'-vinblastine analogue.

  DOI：

  10.1021/ol300173v

文献信息

• [EN] CONJUGATE OF FLUORESCENT DYE FOR THE VISUALIZATION OF PSMA EXPRESSING CELLS<br/>[FR] CONJUGUÉ DE COLORANT FLUORESCENT POUR LA VISUALISATION DE CELLULES EXPRIMANT LE PSMA
  申请人：OBSHCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIU IZVARINO FARMA

  公开号：WO2021002771A1

  公开（公告）日：2021-01-07

  The invention relates to the field of organic and medicinal chemistry, as well as molecular biology, and concerns a new class of compounds for imaging PSMA expressing cells and tissues, such as prostate cancer cells. New diagnostic conjugates for the visualization of pathogenic cells or tissues expressing PSMA, including the PSMA ligand with a linker and a fluorescent dye, the method for its preparation and use are claimed. The technical result of the claimed group of inventions is the high affinity and selectivity of the action of the claimed conjugates in relation to PSMA expressing cells. These compounds allow you to expand the arsenal of diagnostic tools for imaging cells with high level of PSMA expression. The use of an azido derivative of aminopentanoic acid makes it possible to obtain a PSMA vector with a long hydrophobic linker and protected carboxy groups, which in turn facilitates its modification, increases the yield and reduces the amount of solvents used in the process due to a significant increase in the solubility of the starting compound (PSMA vector with a long hydrophobic linker and protected carboxy groups). The key feature of the claimed conjugate is the presence of a long hydrophobic linker in the structure, as well as additional aromatic fragments, the presence of which contributes to better binding of the claimed conjugate to the protein target, due to the involvement of additional interactions between the compound and the hydrophobic pockets in the structure of the hydrophobic tunnel of the protein target.

  该发明涉及有机和药物化学、分子生物学领域，涉及一类用于成像表达PSMA的细胞和组织（如前列腺癌细胞）的新型化合物。声称了用于可视化表达PSMA的病原细胞或组织的新诊断共轭物，包括带有连接剂和荧光染料的PSMA配体，以及其制备和使用方法。所声称的发明组合的技术结果是所声称的共轭物在与PSMA表达细胞的关系中具有高亲和力和选择性的作用。这些化合物可以扩大成像PSMA表达水平高的细胞的诊断工具库。使用氨基戊二酸的偶氮衍生物可以获得具有长疏水连接剂和保护羧基的PSMA载体，从而便于其修饰，增加产量并减少由于起始化合物的溶解度显著增加而在过程中使用的溶剂量。所声称的共轭物的关键特征是结构中存在长疏水连接剂，以及额外的芳香片段，其存在有助于所声称的共轭物与蛋白靶标更好地结合，因为涉及到化合物与蛋白靶标的疏水隧道结构中的疏水口袋之间的额外相互作用。
• [EN] CONJUGATE MONOMETHYL AURISTATIN E TO OBTAIN A COMPOSITION FOR TREATMENT OF PROSTATE CANCER<br/>[FR] MONOMÉTHYL AURISTATINE E CONJUGUÉ PERMETTANT D'OBTENIR UNE COMPOSITION DESTINÉE AU TRAITEMENT DU CANCER DE LA PROSTATE
  申请人：OBSHCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIU IZVARINO FARMA

  公开号：WO2021101407A1

  公开（公告）日：2021-05-27

  This invention is the conjugate of formula (I) for treatment of tumors expressing PSMA, including PSMA-ligand with linker and antineoplastic agent MMAE, the composition for lyophilizate preparation based on it, the dosage form for therapy and obtained by the lyophilization of this composition, PSMA expressing prostate tumor growth inhibition, the solution for infusions or injections containing this dosage form, reconstituted by the solvent, comprising 95% ethyl alcohol and polysorbate 80 within mass ratio (30-60):(70-40), respectively. The technical result of the claimed group of inventions is the high affinity and selectivity of the action of the claimed conjugates in relation to PSMA expressing cells. 6 files of independent points and 6 files of dependent points, 15 illustrations, 27 tables, 7 notes.

  这项发明是用于治疗表达PSMA的肿瘤的公式(I)的共轭物，包括具有连接剂和抗肿瘤剂MMAE的PSMA配体，基于此的冻干制剂制备的组合物，用于治疗的剂型以及通过该组合物的冻干制剂制备的，PSMA表达的前列腺肿瘤生长抑制，注射或静脉注射的溶液，含有该剂型，通过溶剂重组成的，包含95%乙醇和聚山梨醇酯80的质量比(30-60):(70-40)，所述申请的一组发明的技术效果是所述共轭物对PSMA表达细胞具有高亲和力和选择性作用。6个独立点的文件和6个依赖点的文件，15个插图，27个表格，7个注释。
• PROTEIN AND PEPTIDE LIBRARIES
  申请人：Treco Douglas A.

  公开号：US20140234898A1

  公开（公告）日：2014-08-21

  Provided herein are, inter alia, methods for linking an mRNA molecule to a polypeptide (e.g., a peptide or a protein) by linking the mRNA molecule to a linking amino acid in the polypeptide, or by linking the mRNA molecule to a linking tRNA to which the polypeptide is attached, via reactions not catalyzed by the ribosome, and methods for making polypeptide libraries. Also provided are mRNA-protein complexes and mRNA-tRNA-protein complexes, libraries containing these complexes, and methods of using these complexes.

  本文提供了将mRNA分子与多肽（例如肽或蛋白质）连接的方法，其中通过将mRNA分子连接到多肽中的连接氨基酸，或通过将mRNA分子连接到连接tRNA，再将tRNA连接到多肽上，通过非核糖体催化的反应实现连接。同时，还提供了制备多肽库的方法。此外，本文还提供了mRNA-蛋白质复合物和mRNA-tRNA-蛋白质复合物，以及包含这些复合物的库以及使用这些复合物的方法。
• US9422550B2
  申请人：——

  公开号：US9422550B2

  公开（公告）日：2016-08-23
• [EN] PROTEIN AND PEPTIDE LIBRARIES<br/>[FR] BANQUES DE PROTÉINES ET DE PEPTIDES
  申请人：GEN HOSPITAL CORP

  公开号：WO2013019794A1

  公开（公告）日：2013-02-07

  Provided herein are, inter alia, methods for linking an mRNA molecule to a polypeptide (e.g., a peptide or a protein) by linking the mRNA molecule to a linking amino acid in the polypeptide, or by linking the mRNA molecule to a linking tRNA to which the polypeptide is attached, via reactions not catalyzed by the ribosome, and methods for making polypeptide libraries. Also provided are mRNA-protein complexes and mRNA-tRNA-protein complexes, libraries containing these complexes, and methods of using these complexes.